US Patent

US12403140 — Pharmaceutical compositions of nilotinib

Formulation · Assigned to Azurity Pharmaceuticals Inc · Expires 2040-02-18 · 14y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions of nilotinib, specifically amorphous solid dispersions that exhibit enhanced bioavailability in the fasted state.

USPTO Abstract

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., C max , AUC 0-t and/or AUC 0-infinity ) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Drugs covered by this patent

Patent Metadata

Patent number
US12403140
Jurisdiction
US
Classification
Formulation
Expires
2040-02-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Azurity Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.